JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

31.13 0.35

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

30.58

Max

31.53

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-28M 22M
Pardavimai	4.3M 244M
P/E Sektoriaus vid.	11.458 67.147
Pelno marža	9.224
Darbuotojai	293
EBITDA	-22M 52M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+38.13% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	249M 1.8B
Ankstesnė atidarymo kaina	30.78
Ankstesnė uždarymo kaina	31.13

Naujienos nuotaikos

By Acuity

34%

66%

123 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-30 23:08; UTC

Uždarbis

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 23:07; UTC

Uždarbis

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 22:20; UTC

Uždarbis

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

2026-04-30 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise After Gains on Wall Street -- Market Talk

2026-04-30 23:47; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-30 23:47; UTC

Rinkos pokalbiai

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

2026-04-30 23:27; UTC

Rinkos pokalbiai

Liontown Lithium Recovery Expected to Improve -- Market Talk

2026-04-30 23:22; UTC

Uždarbis

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

2026-04-30 23:20; UTC

Rinkos pokalbiai

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

2026-04-30 22:52; UTC

Uždarbis

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 22:33; UTC

Uždarbis

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

2026-04-30 22:32; UTC

Uždarbis

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

2026-04-30 22:32; UTC

Uždarbis

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

2026-04-30 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

2026-04-30 22:11; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-30 22:11; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-30 22:11; UTC

Rinkos pokalbiai

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

2026-04-30 22:05; UTC

Uždarbis

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

2026-04-30 21:57; UTC

Uždarbis

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

2026-04-30 21:56; UTC

Uždarbis

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

2026-04-30 21:56; UTC

Uždarbis

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

2026-04-30 21:55; UTC

Uždarbis

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

2026-04-30 21:54; UTC

Uždarbis

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

2026-04-30 21:54; UTC

Uždarbis

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

2026-04-30 21:53; UTC

Uždarbis

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

2026-04-30 21:49; UTC

Uždarbis

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

2026-04-30 21:49; UTC

Uždarbis

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

38.13% į viršų

12 mėnesių prognozė

Vidutinis 42.89 USD 38.13%

Aukščiausias 72 USD

Žemiausias 25 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

123 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.